OBJECTIVE: Development of a numerical score to measure the microbial spectrum of antibiotic regimens (spectrum score) and method to identify antibiotic de-escalation events based on application of the score. DESIGN: Web-based modified Delphi method. PARTICIPANTS: Physician and pharmacist antimicrobial stewards practicing in the United States recruited through infectious diseases-focused listservs. METHODS: Three Delphi rounds investigated: organisms and antibiotics to include in the spectrum score, operationalization of rules for the score, and de-escalation measurement. A 4-point ordinal scale was used to score antibiotic susceptibility for organism-antibiotic domain pairs. Antibiotic regimen scores, which represented combined activity of antibiotics in a regimen across all organism domains, were used to compare antibiotic spectrum administered early (day 2) and later (day 4) in therapy. Changes in spectrum score were calculated and compared with Delphi participants' judgments on de-escalation with 20 antibiotic regimen vignettes and with non-Delphi steward judgments on de-escalation of 300 pneumonia regimen vignettes. Method sensitivity and specificity to predict expert de-escalation status were calculated. RESULTS: Twenty-four participants completed all Delphi rounds. Expert support for concepts utilized in metric development was identified. For vignettes presented in the Delphi, the sign of change in score correctly classified de-escalation in all vignettes except those involving substitution of oral antibiotics. The sensitivity and specificity of the method to identify de-escalation events as judged by non-Delphi stewards were 86.3% and 96.0%, respectively. CONCLUSIONS: Identification of de-escalation events based on an algorithm that measures microbial spectrum of antibiotic regimens generally agreed with steward judgments of de-escalation status.
OBJECTIVE: Development of a numerical score to measure the microbial spectrum of antibiotic regimens (spectrum score) and method to identify antibiotic de-escalation events based on application of the score. DESIGN: Web-based modified Delphi method. PARTICIPANTS: Physician and pharmacist antimicrobial stewards practicing in the United States recruited through infectious diseases-focused listservs. METHODS: Three Delphi rounds investigated: organisms and antibiotics to include in the spectrum score, operationalization of rules for the score, and de-escalation measurement. A 4-point ordinal scale was used to score antibiotic susceptibility for organism-antibiotic domain pairs. Antibiotic regimen scores, which represented combined activity of antibiotics in a regimen across all organism domains, were used to compare antibiotic spectrum administered early (day 2) and later (day 4) in therapy. Changes in spectrum score were calculated and compared with Delphi participants' judgments on de-escalation with 20 antibiotic regimen vignettes and with non-Delphi steward judgments on de-escalation of 300 pneumonia regimen vignettes. Method sensitivity and specificity to predict expert de-escalation status were calculated. RESULTS: Twenty-four participants completed all Delphi rounds. Expert support for concepts utilized in metric development was identified. For vignettes presented in the Delphi, the sign of change in score correctly classified de-escalation in all vignettes except those involving substitution of oral antibiotics. The sensitivity and specificity of the method to identify de-escalation events as judged by non-Delphi stewards were 86.3% and 96.0%, respectively. CONCLUSIONS: Identification of de-escalation events based on an algorithm that measures microbial spectrum of antibiotic regimens generally agreed with steward judgments of de-escalation status.
Authors: Timothy H Dellit; Robert C Owens; John E McGowan; Dale N Gerding; Robert A Weinstein; John P Burke; W Charles Huskins; David L Paterson; Neil O Fishman; Christopher F Carpenter; P J Brennan; Marianne Billeter; Thomas M Hooton Journal: Clin Infect Dis Date: 2006-12-13 Impact factor: 9.079
Authors: Marin H Kollef; Lee E Morrow; Michael S Niederman; Kenneth V Leeper; Antonio Anzueto; Lisa Benz-Scott; Frank J Rodino Journal: Chest Date: 2006-05 Impact factor: 9.410
Authors: Francisco Alvarez-Lerma; Bernabe Alvarez; Pilar Luque; Francisco Ruiz; Jose-Maria Dominguez-Roldan; Elisabet Quintana; Cesar Sanz-Rodriguez Journal: Crit Care Date: 2006-05-16 Impact factor: 9.097
Authors: Jefferson G Bohan; Richard Remington; Makoto Jones; Matthew Samore; Karl Madaras-Kelly Journal: Open Forum Infect Dis Date: 2016-12-10 Impact factor: 3.835
Authors: Rebekah W Moehring; Deverick J Anderson; Ronda L Cochran; Lauri A Hicks; Arjun Srinivasan; Elizabeth S Dodds Ashley Journal: Clin Infect Dis Date: 2016-12-07 Impact factor: 9.079
Authors: Liesbet De Bus; Wouter Denys; Julie Catteeuw; Bram Gadeyne; Karel Vermeulen; Jerina Boelens; Geert Claeys; Jan J De Waele; Johan Decruyenaere; Pieter O Depuydt Journal: Intensive Care Med Date: 2016-03-30 Impact factor: 17.440
Authors: K R Rivard; V Athans; S W Lam; S M Gordon; G W Procop; S S Richter; E Neuner Journal: Eur J Clin Microbiol Infect Dis Date: 2017-05-23 Impact factor: 3.267
Authors: Alexis Tabah; Matteo Bassetti; Marin H Kollef; Jean-Ralph Zahar; José-Artur Paiva; Jean-Francois Timsit; Jason A Roberts; Jeroen Schouten; Helen Giamarellou; Jordi Rello; Jan De Waele; Andrew F Shorr; Marc Leone; Garyphallia Poulakou; Pieter Depuydt; Jose Garnacho-Montero Journal: Intensive Care Med Date: 2019-11-28 Impact factor: 17.440
Authors: Karl Madaras-Kelly; Makoto Jones; Richard Remington; Christina M Caplinger; Benedikt Huttner; Barbara Jones; Matthew Samore Journal: J Antimicrob Chemother Date: 2015-11-03 Impact factor: 5.790
Authors: Federico Perez; Roberto Viau Colindres; Brigid M Wilson; Elie Saade; Robin L P Jump; Ritu Banerjee; Robin Patel; Scott R Evans; Robert A Bonomo Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 9.079